Author： Prada Patricia O
Publisher： Informa Healthcare
ISSN： 1354-3784
Source： Expert Opinion on Investigational Drugs, Vol.22, Iss.6, 2013-09, pp. : 751-763
Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.
Abstract
Introduction: Some inhibitors of tyrosine kinase, as imatinib, erlotinib and sunitinib have antihyperglycemic effects but the mechanisms are not totally clear. Areas covered: It is well established that insulin resistance and beta-cell failure are hallmarks of type 2 diabetes mellitus (DM2). The present review will discuss the molecular mechanisms that account for insulin resistance and beta-cell failure in DM2, and also the effect of tyrosine kinase inhibitors in these processes. Expert opinion: A better understanding of how these drugs improve the two most important mechanisms of DM2 associated with suggestions of clinical studies will lead to improve the treatment of this disease.
Related content
Novel Tyrosine Kinase Inhibitors in the Treatment of Cancer
Current Drug Targets, Vol. 10, Iss. 6, 2009-06 ,pp. :
Access to resources
Recommend
Novel FLT3 tyrosine kinase inhibitors
Expert Opinion on Investigational Drugs, Vol. 12, Iss. 12, 2003-12 ,pp. :
Protein tyrosine kinase inhibitors in cancer treatment
By Traxler P.M.
Expert Opinion on Therapeutic Patents, Vol. 7, Iss. 6, 1997-06 ,pp. :
Tyrosine kinase inhibitors in cancer treatment (Part II)
By Traxler P.
Expert Opinion on Therapeutic Patents, Vol. 8, Iss. 12, 1998-12 ,pp. :